辉瑞与药明康德达成独家合作及许可协议。 ...

进入12月，药明康德迎来了成立的第25个年头。四分之一世纪的时光，这家CXO企业从上海一间650平 方米的实验室，成长为在亚洲、欧洲、北美拥有超过20个研发生产基地、服务全球数千家客户的一体化 CRDMO赋能平台。在这段发展历程中，药明康德用实践诠释了何谓穿越周期的"长期主义"。 一体化CRDMO模式打通增长通路 药明康德得以在多个经济与行业周期中持续增长，核心驱动力正是其长期坚持的"一体化，端到 端"CRDMO业务模式。这一模式实现了药物发现与研究(R)、工艺开发(D)和商业化生产(M)的无缝贯 通，通过内部高效协同形成增长飞轮。 例如，药明康德在靶向蛋白降解(TPD)领域的发展，正是其CRDMO模式优势的重要体现。早在科学转 化的初期，药明康德就从R端捕捉到创新趋势，于近10年前开始布局相关能力和技术，并跟随前沿科学 陆续构建了涵盖多种分子类型的技术平台。另一方面，R端对下游D&M端业务起到引流作用。如今， 已有超过18.8万种复杂的TPD化合物从药明康德的赋能平台走出，其中70多种已进入临床前候选药物阶 段，10多种已进入后期开发阶段。 在下游，D&M端的规模化、一体化能力，实现技术的快速放大与高效产出 ...

近日，药明康德披露2025年第三季度报告，公司前三季度实现营业收入328.57亿元，同比增长18.61%； 净利润120.76亿元，同比大幅增长84.84%。表面亮眼的业绩背后，却隐藏着利润结构依赖非经常性收 益、国内业务增长乏力、研发投入收缩等多重风险。 利润高增背后：超四成靠"副业"，可持续性存疑 尽管药明康德净利润增速高达84.84%，但其中非经常性损益贡献达25.53亿元，主要来自出售旗下联营 企业股权收益。扣除这部分后，扣非净利润增速降至42.51%，不仅显著低于净利润增速，也落后于凯 莱英、康龙化成等同行业公司。 在CXO行业，企业通过股权投资获取收益并不罕见，但药明康德非经常性收益占净利润比例超过四 成，反映出主营业务盈利能力相对疲软。若公司不能将投资收益占比控制在合理范围，其估值逻辑可能 从"研发服务龙头"向"半PE半VC"模式偏移，影响市场对其持续盈利能力的判断。 增长结构失衡：国内业务近乎零增长，地缘风险加剧 分区域看，药明康德前三季度来自中国客户的收入仅微增0.5%，几乎陷入停滞；而美国客户收入增长 31.9%，欧洲增长13.5%。公司增长高度依赖海外市场，尤其是美国市场。 当前地缘政治 ...

【导读】药明生物、药明康德领涨蓝筹，澳达控股狂飙超370% 12月4日，港股震荡攀升，恒生指数收涨0.68%，报25935.9点；恒生科技指数上涨1.45%，报5615.43点；恒生中国企业指数上涨0.86%，报9106.48点。市场 成交1793.06亿港元，较前一交易日有所增加。 | 恒生指数 | 恒生国灭 | 恒生科技 | | --- | --- | --- | | 25935.90 9106.48 | | 5615.43 | | +175.17 +0.68% +77.93 +0.86% +80.51 +1.45% | | | 恒生指数成份股中65只上涨、21只下跌。其中，药明生物涨7.09%，药明康德（603259）涨5.44%，小米集团涨4.38%。 | 序号 | 名称 | 代码 | 现价 | 淵跌 | 涨跌幅 ▼ | 成交额 | 年初至今 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 药明生物 | 2269 | 32.940 c | 2.180 | 7.09% | 19.91亿 | 87.59% | | 2 | 药明康德 | 2 ...

Core Insights - Hillhouse Capital has completed the acquisition of Nanjing Mingjie Biomedical Testing Co., Ltd, marking another strategic move in the pharmaceutical outsourcing sector [1][4] - This acquisition follows Hillhouse's previous purchase of WuXi AppTec's subsidiaries, indicating a trend of divesting non-core assets by WuXi AppTec to focus on CRDMO models [3][7] Company Overview - Mingjie Biomedical, established in 2016 and headquartered in Nanjing, was previously a subsidiary of WuXi AppTec, which acquired 60% of its shares in 2020 to enhance its drug quality control and analysis capabilities [1][4] - The company provides a comprehensive drug quality research technology platform compliant with global regulatory standards, including FDA, EMA, and NMPA [2][5] Service Capabilities - Mingjie Biomedical's service offerings include small molecule drugs, biopharmaceuticals, complex formulations, excipients, packaging materials, cell and gene therapy products, and medical devices [2][5] - The company operates modern laboratories in Nanjing and Shanghai, adhering to cGMP standards, and offers services such as trace residue analysis, impurity separation and purification, structural identification, and compatibility studies [2][5] Regulatory Compliance - In 2023, both laboratories successfully passed FDA inspections and multiple CFDA audits, demonstrating a robust international quality management system and compliance capabilities [2][5]

Core Viewpoint - The company, WuXi AppTec, experienced a decline of 2.01% in stock price, with a trading volume of 4.105 billion yuan and a total market capitalization of 261.437 billion yuan [1] Group 1: Company Overview - WuXi AppTec is a leading international open-access capability and technology platform providing comprehensive and integrated new drug research and production services for the global biopharmaceutical industry [2] - The company is a domestic leader in the pharmaceutical outsourcing industry and one of the earliest integrated CRO and CMO companies in China, with a management team holding over 200 authorized and pending patents [2] - The main business involves the discovery, research, and production of small molecule chemical drugs, offering a full-spectrum integrated platform service to global pharmaceutical companies [2][7] Group 2: Financial Performance - For the period from January to September 2025, WuXi AppTec achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61%, and a net profit attributable to shareholders of 12.076 billion yuan, with a year-on-year increase of 84.84% [7] - The company’s revenue from overseas accounts for 78.67%, benefiting from the depreciation of the Renminbi [3] Group 3: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders reached 274,100, an increase of 16.39% from the previous period, with an average of 9,024 circulating shares per person [7] - The company has distributed a total of 14.060 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the past three years [8] - The main shareholders include Hong Kong Central Clearing Limited, which holds 249 million shares, a decrease of 52.6071 million shares from the previous period [8][9]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年12月2日 備註： 第 1 頁 共 11 頁 v 1.1.1 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 | RMB | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 2. 股份分 ...

近期，药明康德持续受到资本市场关注，一系列股东减持与资产优化举措引发了市场讨论。然而，深入 分析其战略逻辑与行业地位不难发现，公司长期价值根基依然稳固，投资者对其未来发展的信心并未动 摇。 10月29日，药明康德发布公告称，17家股东因自身资金需求计划减持不超过公司总股本2%的A股股 份，比例可控。随后在11月26日，公司进一步披露了阶段性减持进展：2025年11月20日至25日期间，相 关股东合计减持1182.79万股，占总股本的0.3963%。值得关注的是，在此期间公司股价逆势上涨 1.19%，截至11月25日收盘报94.31元。这一市场表现表明，尽管面临股东减持带来的情绪波动，更多投 资者仍看好公司的长期发展前景。 股东减持作为资本市场中的常见行为，应在合理监管框架下理性看待。对药明康德这类已步入成熟发展 阶段的规模化企业而言，股东适度减持多属于正常的资产配置调整。从药明康德此次减持计划的披露情 况来看，整个过程符合监管要求，规范且透明。 另外，公告也指出，大宗交易的买方在受让后6个月内不得转让，这种"锁定期"约束也能降低二级市场 快速抛售的风险，确保减持节奏温和可控，压抑缓解冲击。 自2018年实现" ...

Core Viewpoint - The investment philosophy of Duan Yongping emphasizes understanding the intrinsic value of a company beyond market fluctuations, as illustrated by the recent share reduction news from WuXi AppTec [1] Group 1: Shareholder Actions - On October 29, WuXi AppTec announced a plan for its actual controller to reduce shares by up to 2% of the total share capital through centralized bidding and/or block trading [1] - The market reacted strongly to the news, despite the reduction being relatively small and regulated, indicating a growing desensitization among investors regarding the negative perception of share reductions [1] Group 2: Company Performance - Since October 30, WuXi AppTec's stock has outperformed the market, even increasing by 1.19% during the share reduction period from November 20 to 25 [2] - WuXi AppTec has established a unique business model since its founding in 2000, focusing on assisting pharmaceutical companies in lowering development barriers and accelerating new drug launches [2] Group 3: Financial Metrics - Investors who held WuXi AppTec shares since its IPO have seen a return of 12.3 times by September this year, supported by a solid business model [3] - As of the first half of this year, WuXi AppTec's ongoing business orders have achieved a compound growth rate of 38% since 2018, nearing 60 billion [3] - By the third quarter of 2025, WuXi AppTec's revenue is projected to exceed 32.857 billion, with a year-on-year growth of 18.61% and an increase in net profit margin from 26.5% to 32.1% [3] Group 4: Shareholder Returns - WuXi AppTec's expected earnings per share in 2025 will be seven times that of its IPO, with a total of 20 billion allocated for cash dividends and share buybacks over the past seven years [4] - The company has implemented a nearly 7 billion shareholder return plan for 2025, which represents 72% of the net profit for 2024 [4] - For the first three quarters of 2025, WuXi AppTec's net profit attributable to shareholders reached 12.076 billion, reflecting an 84.84% year-on-year increase [4] Group 5: Long-term Belief - Achieving a 12-fold return over seven years requires a strong belief in the long-term value of the company and the power of belief itself [5]